Related Experiment Videos
New agents for scintigraphy in rheumatoid arthritis
M H de Bois1, E K Pauwels, F C Breedveld
1Department of Rheumatology, University Hospital, Leiden, The Netherlands.
European Journal of Nuclear Medicine
|November 1, 1995
Summary
Radiopharmaceuticals aid in detecting rheumatoid arthritis (RA) activity. Advanced imaging techniques like technetium-99m labelled human immunoglobulin (99mTc-IgG) scintigraphy offer better assessment and treatment guidance for RA patients.
Area of Science:
- Nuclear medicine
- Rheumatology
- Radiopharmaceutical imaging
Background:
- Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting joints.
- Radiopharmaceuticals have been utilized for RA detection and treatment since the 1950s.
- Joint scintigraphy plays a crucial role in assessing RA activity.
Purpose of the Study:
- To review the current status of joint scintigraphy in rheumatoid arthritis.
- To explore the role of various radiopharmaceuticals in RA detection and management.
- To discuss potential future developments in radiopharmaceutical imaging for RA.
Main Methods:
- Review of non-specific radiopharmaceuticals (radiolabelled leucocytes, 99mTc-IgG).
- Consideration of specific targeting radiopharmaceuticals (radiolabelled antibodies, somatostatin receptor imaging).
- Evaluation of emerging radiopharmaceuticals (anti-CD4, anti-E-selectin antibodies, J001, cytokines).
Main Results:
- Radiopharmaceuticals allow direct imaging of joints, including difficult-to-assess areas.
- 99mTc-IgG scintigraphy effectively differentiates RA activity levels, aiding treatment selection.
- Promising results observed with radiolabelled anti-CD4, anti-E-selectin antibodies, and somatostatin receptor imaging.
Conclusions:
- Radiopharmaceuticals are valuable tools for RA assessment and management.
- Advanced radiopharmaceutical imaging offers improved diagnostic capabilities for RA.
- Future research into novel radiotracers holds promise for enhanced RA imaging and treatment.